Page 12 - Sanket Koul

Indian drugmakers gear up for ₹600-800 cr insulin pen market post-Novo exit

Novo Nordisk to phase out insulin pens and cartridges in India; Eris, Wockhardt and Lupin prepare to capture Rs 600-800 crore market opportunity from FY26 onwards

Developers eye festival season demand, GST cuts to revive housing sales

Real estate developers expect GST cuts on inputs and festive buying sentiment to spur housing demand across luxury, mid-segment and Tier-2 cities after a lull in sales

Rise in H-1B fee likely to hit OPT plan of Indian students: Experts

If H-1B visas become harder to secure, the OPT period risks being viewed as a temporary stopgap rather than a pathway to stable employment

Brokers' body resolves differences with MagicBricks after disrespect row

In May this year, NAR India had directed its members to cease all listings, advertisements, and business transactions with MagicBricks and avoid all engagement with the platform

India leads global flex office market, to cross 100 mn sq ft by 2026: C&W

India has topped the global flex office maturity index, with Cushman and Wakefield projecting stock to cross 100 mn sq ft by 2026 on strong demand and operator expansion

CDSCO flags 3 spurious drugs, 94 not of standard quality in August

CDSCO flagged three spurious drugs, including Pan D, Pan 40 and diazepam injection, and listed 94 medicines as not of standard quality in its August 2025 surveillance update

Metropolis Healthcare acquires Kolhapur-based pathlab chain for ₹17 crore

Metropolis added that the move is expected to enhance productivity and drive overall profitability across its network of laboratories operating in the region

Indian pharma faces US revenue slowdown amid scrutiny, tariffs: ICRA

ICRA projects Indian pharma firms' US revenue growth to slow due to price erosion, USFDA scrutiny and tariff risks, while high dependence on Chinese APIs persists despite PLI

Mankind joins hands with OpenAI to institutionalise AI in operations

"GPT-powered dashboards will be used to provide real-time, data-driven insights across R&D, supply chain and commercial operations," a company executive told Business Standard

Hospitals vs insurers: Policyholders bear the brunt of rising medical costs

The simmering conflict came to a head last month when Niva Bupa suspended cashless services at Max Hospitals on August 16, citing unresolved reimbursement issues

Medical device makers ask for extending ITC on services, capital goods

Industry body Aimed says proposed balanced reforms could help reduce healthcare costs for consumers

NMC announces 6,850 new MBBS seats for 2025-26 in line with expansion plan

The National Medical Commission has approved 6,850 new MBBS seats for 2025-26, aligning with the Centre's plan to expand medical education and improve India's doctor-patient ratio

Indian real estate sector expects wave of reforms after SC judgment

2-judge Bench issued a wide-ranging set of 12 binding directions, including framing of specific guidelines for insolvency proceedings in real estate

NPPA asks pharma, medtech firms to cut prices after GST rate reduction

NPPA directs pharma and medical device makers to revise MRPs after GST cut to 5 per cent, while making relabelling of old stock voluntary subject to compliance

HC ruling on JDAs to ease costs, boost project viability, say developers

Legal experts caution of challenge in SC, also clarity would be needed for settling ITC

Pharma, medtech bodies seek transition time and simpler refunds

Industry bodies asked the govt for a three-month transition period, use of old packaging, and a simpler GST refund mechanism to avoid supply chain disruptions in healthcare

Contractors, hoteliers push for GST fixes, clarity on input tax credit

Urge CBIC to implement a special GST payment mechanism

Somerset may close third healthcare fund worth $250 mn by October

The final close is expected next month, with the fund on track to potentially exceed its target.

Parl panel asks Centre to decentralise PMJAY to address accessibility gaps

Panel recommends strengthening existing school and college-based health education programmes on nutrition, fitness, and mental well-being

Mankind Pharma gets CDSCO nod for Phase 1 trials for novel autoimmune drug

Mankind Pharma has received CDSCO approval to initiate Phase 1 trials of MKP11093, a novel JAK-1 inhibitor for autoimmune disorders, as part of its expanding R&D pipeline